Subtopic Deep Dive
VEGF Pathogenesis in Retinopathy of Prematurity
Research Guide
What is VEGF Pathogenesis in Retinopathy of Prematurity?
VEGF pathogenesis in retinopathy of prematurity describes the biphasic role of vascular endothelial growth factor, where hyperoxia suppresses VEGF leading to vaso-obliteration followed by relative hypoxia inducing neovascularization.
Molecular studies using animal models show hyperoxia down-regulates VEGF, halting retinal vessel growth (Pierce, 1996, 505 citations). Subsequent hypoxia triggers excessive VEGF-driven neovascularization (Alon et al., 1995, 1603 citations; Chen and Smith, 2007, 594 citations). Human trials demonstrate anti-VEGF agents like bevacizumab treat stage 3+ ROP effectively in zone I (Mintz-Hittner et al., 2011, 1412 citations). Over 10 key papers elucidate these mechanisms.
Why It Matters
Understanding VEGF's biphasic role guides targeted therapies beyond laser treatment, as intravitreal bevacizumab monotherapy improves zone I ROP outcomes while allowing peripheral vessel development (Mintz-Hittner et al., 2011). Insights from oxygen-regulated VEGF models inform hyperoxia management protocols to prevent vaso-obliteration (Pierce, 1996). Systematic reviews highlight needs for long-term studies on anti-VEGF effects on neurodevelopment (Sankar et al., 2018). These advances reduce blindness risk in preterm infants, affecting millions annually.
Key Research Challenges
Biphasic VEGF Regulation
Hyperoxia suppresses VEGF causing vaso-obliteration, while hypoxia induces pathological neovascularization, complicating timing of interventions (Pierce, 1996; Alon et al., 1995). Models must replicate preterm oxygen fluctuations accurately. Therapeutic windows remain narrow.
Anti-VEGF Long-term Effects
Bevacizumab treats acute ROP but risks delayed systemic effects and neurodevelopmental outcomes require childhood follow-up (Mintz-Hittner et al., 2011; Sankar et al., 2018). Zone II efficacy lags behind zone I. Optimal dosing lacks consensus.
Translating Animal Models
Rodent hyperoxia models capture VEGF dynamics but differ from human preterm retina maturation (Chen and Smith, 2007; Hartnett, 2014). Human vitreous VEGF analyses are invasive. Bridging preclinical to clinical trials challenges validation.
Essential Papers
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
Tamir Alon, Itzhak Hemo, Ahuva Itin et al. · 1995 · Nature Medicine · 1.6K citations
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang · 2011 · New England Journal of Medicine · 1.4K citations
Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II diseas...
Retinopathy of prematurity
Jing Chen, Lois E. H. Smith · 2007 · Angiogenesis · 594 citations
Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity
Eric A. Pierce · 1996 · Archives of Ophthalmology · 505 citations
Down-regulation of VEGF expression by hyperoxia may be partly responsible for the vaso-obliteration and cessation of normal retinal blood vessel growth observed in premature infants in whom ROP dev...
Development and pathology of the hyaloid, choroidal and retinal vasculature
Magali Saint‐Geniez, Patrìcia A. D'Amore · 2004 · The International Journal of Developmental Biology · 407 citations
During embryogenesis, the development and differentiation of the eye requires the concomitant formation of the neural/glial elements along with a dense vascular network. The adult neural retina is ...
Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity
M. Elizabeth Hartnett · 2014 · Ophthalmology · 336 citations
Pathogenesis of retinopathy of prematurity
Lois E. H. Smith · 2003 · Seminars in Neonatology · 284 citations
Reading Guide
Foundational Papers
Start with Alon et al. (1995, 1603 citations) for VEGF survival role in retinal vessels; Pierce (1996, 505 citations) for oxygen-VEGF regulation in ROP models; Mintz-Hittner et al. (2011, 1412 citations) for clinical anti-VEGF validation.
Recent Advances
Hartnett (2014, 336 citations) details severe ROP mechanisms; Sankar et al. (2018, 221 citations) reviews anti-VEGF outcomes; Wooff et al. (2019, 251 citations) explores IL-1/VEGF inflammation links.
Core Methods
Hyperoxia-induced mouse models (Pierce, 1996); intravitreal bevacizumab injection trials (Mintz-Hittner et al., 2011); vitreous humor VEGF quantification; retinal vessel morphometry (Chen and Smith, 2007).
How PapersFlow Helps You Research VEGF Pathogenesis in Retinopathy of Prematurity
Discover & Search
Research Agent uses searchPapers('VEGF oxygen regulation ROP') to find Pierce (1996), then citationGraph reveals Alon et al. (1995, 1603 citations) as highly cited predecessor, and findSimilarPapers expands to Chen and Smith (2007). exaSearch uncovers related oxygen-VEGF mechanisms across 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Mintz-Hittner et al. (2011) to extract zone I vs. zone II efficacy data, verifyResponse with CoVe cross-checks bevacizumab benefits against Sankar et al. (2018) review, and runPythonAnalysis plots VEGF expression trends from Pierce (1996) abstracts using pandas for statistical verification. GRADE grading assesses evidence quality for anti-VEGF trials.
Synthesize & Write
Synthesis Agent detects gaps in long-term neurodevelopmental data post-anti-VEGF (Sankar et al., 2018), flags contradictions between animal models and human outcomes, then Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates Alon et al. (1995), and latexCompile generates ROP pathogenesis review PDF. exportMermaid visualizes biphasic VEGF phases.
Use Cases
"Analyze VEGF levels from hyperoxia mouse models in Pierce 1996 and plot expression changes"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Pierce 1996) → runPythonAnalysis(pandas plot VEGF downregulation) → matplotlib graph of vaso-obliteration phase.
"Write LaTeX review on bevacizumab efficacy in zone I ROP citing Mintz-Hittner"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft section) → latexSyncCitations(Mintz-Hittner 2011, Sankar 2018) → latexCompile → PDF with biphasic model diagram.
"Find code for retinal vessel segmentation in ROP VEGF studies"
Research Agent → searchPapers(VEGF ROP imaging) → paperExtractUrls → paperFindGithubRepo → Code Discovery → githubRepoInspect → runnable ImageJ/Fiji script for neovascularization quantification.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ VEGF ROP papers) → citationGraph → DeepScan(7-step analysis with GRADE checkpoints on Mintz-Hittner et al.) → structured report on pathogenesis. Theorizer generates hypotheses on IL-1/VEGF interactions from Wooff et al. (2019) and Sapieha et al. (2010). Chain-of-Verification ensures no hallucinations in biphasic model synthesis.
Frequently Asked Questions
What defines VEGF pathogenesis in ROP?
Hyperoxia down-regulates VEGF causing phase 1 vaso-obliteration, followed by phase 2 hypoxia-driven neovascularization (Pierce, 1996; Alon et al., 1995).
What are key methods studying VEGF in ROP?
Hyperoxia mouse models measure VEGF mRNA/protein (Pierce, 1996), human vitreous ELISA quantifies levels, and intravitreal anti-VEGF trials assess outcomes (Mintz-Hittner et al., 2011).
What are seminal papers on this topic?
Alon et al. (1995, 1603 citations) shows VEGF as survival factor; Pierce (1996, 505 citations) links oxygen to VEGF regulation; Mintz-Hittner et al. (2011, 1412 citations) validates bevacizumab.
What open problems persist?
Long-term neurodevelopmental effects of anti-VEGF (Sankar et al., 2018), zone II treatment optimization (Mintz-Hittner et al., 2011), and human-specific model translation (Hartnett, 2014).
Research Retinopathy of Prematurity Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching VEGF Pathogenesis in Retinopathy of Prematurity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers